Search

Your search keyword '"Malizia, G"' showing total 274 results

Search Constraints

Start Over You searched for: Author "Malizia, G" Remove constraint Author: "Malizia, G"
274 results on '"Malizia, G"'

Search Results

1. T.07.7: CHARACTERISTICS AND MANAGEMENT OF HEPATOCELLULAR CARCINOMA (HCC) IN SICILY: FIRST RESULTS OF THE HCC SICILY MULTIDISCIPLINARY NETWORK

2. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents

3. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct‐acting antivirals? A prospective multicentre study

4. Progressive right ventricular dysfunction and exercise impairment in patients with heart failure and diabetes mellitus: insights from the T.O.S.CA. Registry

5. Multiple hormonal and metabolic deficiency syndrome predicts outcome in heart failure: the T.O.S.CA. Registry

6. Applicazione del Training Mindfulness in bambini con ADHD

10. Multiple hormonal and metabolic deficiency syndrome in chronic heart failure: rationale, design, and demographic characteristics of the T.O.S.CA. Registry

21. PC.01.10 LIVER AND CARDIOVASCULAR MORTALITY AFTER DAAS: DATA FROM THE RESIST-HCV COHORT

22. OC.07.1 DIRECT ACTING ANTIVIRALS AFTER SUCCESSFUL TREATMENT OF EARLY HEPATOCELLULAR CARCINOMA IMPROVE SURVIVAL AND REDUCE HEPATIC DECOMPENSATION IN HCV-CIRRHOTIC PATIENTS

23. Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients

24. P119 Surgical recurrence in Crohn’s disease patients with severe post-operative endoscopic recurrence: risk difference between purely anastomotic lesions and lesions limited to the neoterminal ileum

35. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents

36. Disease outcomes after DAA-induced SVR: data from the resist-HCV cohort

43. Non-invasive tools to ruling out large varices: RESIST-HCV vs Baveno VI criteria in a large cohort of patients with HCV cirrhosis

44. Efficacy and safety of 12-week DAA regimens in HCV genotype 1b patients with compensated cirrhosis: data of RESIST-HCV Cohort

50. The T.O.S.C.A. Project: Research, Education and Care

Catalog

Books, media, physical & digital resources